New ANDA Review Pathways: Should You Be A Priority Or Expedited?
Executive Summary
Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.
You may also be interested in...
For ANDAs, Pre-Submission Facility Correspondence Has Improved, But Still Not Ideal
US FDA wants the program, intended to help speed ANDA approvals, utilized more, but industry still questions the information that must be submitted.
For ANDAs, Pre-Submission Facility Correspondence Has Improved, But Still Not Ideal
US FDA wants the program, intended to help speed ANDA approvals, utilized more, but industry still questions the information that must be submitted.
Generic Drugs: ‘Competitive’ Exclusivity Benefited Few Sponsors But Is Increasingly Popular
The six months of additional exclusivity from US FDA’s CGT program appears to have kept some generic sponsors from the market, and didn’t even prompt others to enter quickly, but use of the competitive generic exclusivity program continues to grow.